Key Takeaways Bristol Myers expands Opdivo into new cHL settings, broadening reach across treatment lines.Label expansions and pipeline progress aim to offset generic pressure on legacy drugs like Revlimid.Oncology competition intensifies as Merck and Pfizer advance bispecifics and diversified cancer pipelines.Bristol Myers Squibb (BMY) recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo.The FDA approved Opdivo in combination wi ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

Even the most dedicated income investors often avoid healthcare titles, especially those in the high-capital-expenditures pharmaceutical sector. As ever, though, we can find exceptions. Here's a brief look at two that buck the sector's general trend by not only paying dividends regularly, but also raising them on a consistent basis. Say hello to AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). Will AI create the world's first trillionaire? Our team just released a report on the one little-known ...

A big theme for investors in 2026 has been to buy dividend stocks. They can make for valuable investments for not only the recurring income they can generate but also their stability, as they are often fairly safe investments to hang on to. Companies that pay dividends normally have strong financials that enable them to make regular payments -- but that doesn't make them guarantees. Bristol Myers Squibb (NYSE: BMY) is a top healthcare company that pays a great dividend. It currently yields 4.4%, which is f ...

Freelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to financial data. Working with teams that include senior editors, investment strategists, marketing managers, data analysts, and executives, I contribute ideas to help make content relevant, accessible, and measurable. Having ...

Core Viewpoint - Investors are facing significant market volatility, making it essential to consider companies that can perform well regardless of economic conditions, such as Bristol Myers Squibb, which offers a solid dividend stock opportunity [1]. Group 1: Company Overview - Bristol Myers Squibb is a leading player in the defensive pharmaceutical industry, known for its essential lifesaving drugs that maintain consistent demand through various economic conditions [2]. - The company's portfolio includes oncology, immunology, and rare diseases, although it has faced challenges due to patent cliffs, resulting in modest revenue growth [3]. Group 2: Financial Performance - In the fourth quarter, Bristol Myers reported sales of $12.5 billion, reflecting a year-over-year increase of only 1% [3]. - The growth portfolio, primarily consisting of therapies approved since 2019, generated $7.4 billion in sales during the fourth quarter, marking a 16% year-over-year increase [6]. Group 3: Dividend and Valuation - Bristol Myers offers a forward dividend yield of 4.2%, significantly higher than the S&P 500 average of 1.2%, and has increased its dividends by 65.8% over the past decade [6]. - The company's cash payout ratio stands at 39.3%, indicating potential for further dividend growth [6]. - Currently, Bristol Myers is trading at 9.5 times forward earnings, which is below the healthcare sector's average of 17.1 times [7].

Core Insights - Bristol Myers Squibb has received expanded approvals for Opdivo® (nivolumab) in the treatment of classical Hodgkin lymphoma in the U.S. and by the European Medicines Agency (EMA) [1] Group 1 - The approval marks a significant transformation in the treatment paradigm for classical Hodgkin lymphoma, indicating a shift towards more effective therapeutic options [1] - Opdivo® is now recognized for its potential to improve patient outcomes in this specific cancer type, reflecting advancements in immunotherapy [1] - The expanded indication is expected to enhance the company's market position and drive revenue growth in the oncology segment [1]

Core Insights - Bristol Myers (BMY) has received FDA approval for Sotyktu, expanding its label to include adults with active psoriatic arthritis (PsA), which enhances the drug's commercial profile and lifecycle potential [1][4] - Sotyktu is the first TYK2 inhibitor approved for PsA, offering a differentiated oral therapy in a market traditionally dominated by injectable biologics [2][4] - The label expansion strengthens Bristol Myers' immunology franchise and diversifies its revenue streams beyond oncology, addressing both skin and joint manifestations of psoriatic arthritis [3][10] Market Dynamics - The PsA market is highly competitive, with established biologics and oral agents already present, making commercial execution critical for Sotyktu [4][10] - Sotyktu's sales reached $291 million in 2025, reflecting a 19% increase from 2024, and it is also being evaluated for lupus and Sjogren's Disease [5] Competitive Landscape - Sotyktu faces competition from Amgen's Otezla and Novartis' Cosentyx, both of which have established market presence and multiple indications [7][8][10] - Cosentyx generated $6.7 billion in revenues for Novartis in 2025, marking an 8% growth from 2024, highlighting the competitive pressure in the market [9] Financial Performance - Bristol Myers shares have declined by 4.8% over the past year, contrasting with the industry's growth of 11.2% [13] - The company is trading at a price/earnings ratio of 9.34x forward earnings, which is lower than the large-cap pharma industry's average of 16.92x [14] - The Zacks Consensus Estimate for 2026 EPS has increased to $6.26 from $6.15, indicating positive revisions in earnings expectations [16]

• Bristol-Myers Squibb shares are experiencing downward pressure. Why is BMY stock retreating?Hodgkin lymphoma (HL) is a cancer in which multinucleated Reed–Sternberg cells (RS cells) are present in the lymph nodes.Autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.Three or more lines of systemic therapy that include autologous HSCT.Nivolumab received accelerated approval for these indications in 2016 and 2017, respectively.Bristol Myers Efficacy and SafetyEfficacy of nivolum ...

US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma | Reuters March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's (BMY.N), opens new tabcombination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin's lymphoma. Sign up here. Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licens ...